Home > Insider Trading > Filing (0001213900-22-004647)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1290149	Sierra Oncology Inc.	SRRA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1509160	Vivo Ventures Fund Vii, L.p.	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1538309	Vivo Ventures Vii Affiliates Fund, L.p.	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1565020	Vivo Ventures Vii, Llc	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1726403	Vivo Opportunity Fund, L.p.	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1728970	Vivo Opportunity, Llc	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1750117	Vivo Capital Fund Ix, L.p.	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1750698	Vivo Capital Ix, Llc	192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-31	800,000	$27.00	2,735,853	No	4	P	Indirect	By Vivo Opportunity Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Vivo Opportunity Fund, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	161,712	Indirect	By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P.
Common Stock	431,947	Indirect	By: Vivo Capital Fund IX, L.P.

Footnotes

Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.